PIV5-BASED COVID-19 VACCINE Russian patent published in 2025 - IPC A61K39/215 C12N15/45 

FIELD: biotechnology; medicine.

SUBSTANCE: invention relates to biotechnology, virology and medicine. Disclosed is an expression vector based on a virus containing parainfluenza virus 5 (PIV5) genome. Vector contains a heterologous nucleotide sequence providing expression of S-protein of coronavirus from coronavirus 2 of severe acute respiratory syndrome (SARS-CoV-2). Heterologous nucleotide sequence is inserted between the low-molecular weight hydrophobic protein (SH) gene and the hemagglutinin-neuraminidase (HN) gene in the PIV5 genome, and the cytoplasmic tail of the S-protein of the coronavirus has been replaced with a cytoplasmic tail of the fusion protein (F) PIV5. Disclosed are: a viral particle for the expression of a heterologous spike-like (S) glycoprotein of a coronavirus, comprising an expression vector; a composition for expressing a heterologous spike (S) glycoprotein of a coronavirus, comprising an expression vector and/or a viral particle; method of providing expression of heterologous spike (S) glycoprotein of coronavirus in a cell; a method of inducing an immune response in a subject to a coronavirus spike (S) glycoprotein; method of vaccinating a subject against coronavirus disease (COVID-19), wherein the method involves administering an expression vector based on a virus, a viral particle or a composition to a subject.

EFFECT: invention provides constructs based on parainfluenza virus type 5 (PIV5), providing expression of SARS-CoV-2 spike (S) coat protein, for use as safe, stable and effective vaccines against COVID-19.

10 cl, 90 dwg, 4 tbl, 4 ex